C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)

Nazanin Moghbeli; Ajay J Kirtane; Kausik K Ray; Sabina A Murphy; C Michael Gibson; Eugene Braunwald; Christopher P Cannon; TIMI Study Group

doi:10.1016/j.amjcard.2005.04.033

C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)

Am J Cardiol. 2005 Sep 1;96(5):635-8. doi: 10.1016/j.amjcard.2005.04.033.

Authors

Nazanin Moghbeli¹, Ajay J Kirtane, Kausik K Ray, Sabina A Murphy, C Michael Gibson, Eugene Braunwald, Christopher P Cannon; TIMI Study Group

Affiliation

¹ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 16125484
DOI: 10.1016/j.amjcard.2005.04.033

Abstract

We investigated the role of inflammation, as measured by high-sensitivity C-reactive protein (CRP) levels, in cardiovascular risk in smokers who have acute coronary syndrome. Despite fewer traditional risk factors, smokers who had acute coronary syndrome had higher CRP levels than did nonsmokers (7.0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Angina, Unstable / blood*
Angina, Unstable / epidemiology
Angina, Unstable / physiopathology
Biomarkers / blood
C-Reactive Protein / metabolism*
Electrocardiography*
Humans
Lung Diseases / blood
Lung Diseases / etiology
Middle Aged
Myocardial Infarction / blood*
Myocardial Infarction / epidemiology
Myocardial Infarction / physiopathology
Randomized Controlled Trials as Topic
Risk Factors
Severity of Illness Index
Smoking / adverse effects
Smoking / blood*
Survival Rate
Syndrome

Substances

Biomarkers
C-Reactive Protein